INBP 8-K: SEC filing
Filed with the SEC on · accession 0001437749-26-036730
INBP filed a 8-K (current report) with the SEC on Nov 13, 2026. Integrated Biopharma, Inc. furnished a press release announcing its financial results for the quarter ended September 30, 2026.
Summary of the filing
Integrated Biopharma, Inc. furnished a press release announcing its financial results for the quarter ended September 30, 2026. The filing is an earnings release under Item 2.02 of Form 8-K.
Key details
✦ Ask GOAX AI about this filing — what it means for INBP, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for INBP?
Click hereFrequently asked questions
What did INBP file with the SEC on Nov 13, 2026?
INBP filed a 8-K (SEC filing). Integrated Biopharma, Inc. furnished a press release announcing its financial results for the quarter ended September 30, 2026. The filing is an earnings release under Item 2.02 of Form 8-K.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other INBP SEC filings
Get alerts when INBP files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days